Table 2.

Recent studies about CAR-T/NK in CSC therapy.

Year	Author	CSC target	Immune cell	Tumor	References
2015	Zhu et al.	CD133	T cell	Glioblastoma	(57)
2015	Deng et al.	EpCAM	T cell	Prostate cancer	(81)
2017	Vita Golubovskaya	CD47	T cell	Pancreatic cancer	(82)
2018	Song et al.	CD44/Her-2	T cell	Gastric cancer	(83)
2018	Wang et al.	CLL-1	T cell	AML	(14)
2018	An et al.	CD38	T cell	Myeloma	(84)
2019	Hu et al.	CD133	T cell	Glioma	(85)
2019	Zhou et al.	EpCAM	T cell	Solid tumor	(61)
2019	Zhang et al.	EpCAM	T cell	CRC	(62)
2021	Anna Stornaiuolo et al.	CD44	T cell	Solid tumor	(73)
2021	Fu et al.	EpCAM	T cell	Ovarian cancer	(60)
2021	Nian et al	EpCAM	T cell	AML	(86)
2017	Rüdiger Klapdor et al.	CD133	NK92 cell	Ovarian cancer	(63)
2019	Rüdiger Klapdor et al.	CD24	NK92 cell	Ovarian cancer	(64)
2019	Zhang et al.	EpCAM	NK92 cell	CRC	(87)

AML, acute myelocytic leukemia; CRC, colorectal cancer.